Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59–65
Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar J, Lopez-Botet M, Duggan-Keen M, Stern P (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95
Ruiz-Cabello F, Cabrera T, Lopez-Nevot M, Garrido F (2002) Impaired surface antigen presentation in tumours: implications for T cell-based immunotherapy. Semin Cancer Biol 12:15–24
Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumour growth. Immunol Today 21:455–464
Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13
Bjorkman PJ, Parham P (1990) Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 59:253–288
Natarajan K, Li H, Mariuzza RA, Margulies DH (1999) MHC class I molecules, structure and function. Rev Immunogenet 1:32–46
Koopman LA, van der Slik AR, Giphart MJ, Fleuren GJ (1999) Human leukocyte antigen class I gene mutations in cervical cancer. J Natl Cancer Inst 91:1669–1677
Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern P (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401–411
Koopman LA, Corver W, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961–976
York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369–396
Gromme M, Neefjes J (2002) Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 39:181–202
Van Kaer L (2002) Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60:1–9
York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock K (2002) The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 3:1177–1184
Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leukocyte antigen class I Antigen Processing Machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11:2552–2560
Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S (2005) Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumours. Clin Cancer Res 11:8304–8311
Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129–138
Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B (2001) Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:1211–1220
Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335–340
Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA, Stern PL (1995) Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72:405–411
Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ (1994) Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69:1176–1181
Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ (1994) The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 101:5–12
Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ (1995) Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 57:366–375
van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ (1996) Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 62:33–41
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256
Ruiz C, Seibt S, Kuraya KA, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Souter G (2005) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118:2190–2194
Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306
Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177–188
Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918–1926
Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66:185–194
Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299:139–151
Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62:385–393
Hattori A, Kitatani K, Matsumoto H, Miyazawa S, Rogi T, Tsuruoka N, Mizutani S, Natori Y, Tsujimoto M (2000) Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells. J Biochem 128:755–762
Saric T, Chang S, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL (2002) An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3:1169–1176
Shibata D, Ando H, Iwase A, Nagasaka T, Hattori A, Tsujimoto M, Mizutani S (2004) Distribution of adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase (ERAP)-1 in human uterine endometrium. J Histochem Cytochem 52:1169–1175
Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren GJ (2002) Transforming growth factor-beta1 induces tumour stroma and reduces tumour infiltrate in cervical cancer. Hum Pathol 33:1193–1199
Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans S, Kennedy S, Kramer MD, Nielsen B, Schmitt M (1998) Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 34:1334–1340
Falk K, Rotzschke O (2002) The final cut: how ERAP1 trims MHC ligands to size. Nat Immunol 3:1121–1122
Chang SC, Momburg F, Bhutani N, Goldberg AL (2005) The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci USA 102:17107–17112
Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM (2005) Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 6:689–697
Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7:103–112
Yan J, Parekh VV, Mendez-Fernandez Y, Olivares-Villagomez D, Dragovic S, Hill T, Roopenian DC, Joyce S, Van Kaer L (2006) In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 203:647–659
Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167:5420–5428
Barnden MJ, Purcell AW, Gorman J, McCluskey J (2000) Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J Immunol 165:322–330
Garbi N, Tan P, Diehl AD, Chambers BJ, Ljunggren H, Momburg F, Hammerling GJ (2000) Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 1:234–238
Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ (2000) Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107–117
Gostout BS, Poland GA, Calhoun ES, Sohni Y, Giuntoli RL, McGovern RM, Sloan J, Cha S, Persing DH (2003) TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 88:326–332
Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C, Shi X, Chen D, Shen Y, Ke Y (2005) LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 26:1280–1284
Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6–10
Young NT, Mulder A, Cerundolo V, Claas FH, Welsh KI (1998) Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines. Tissue Antigens 52:368–373